Pinealon

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

The Pinealon clinical and preclinical literature is predominantly Russian, centered around Khavinson's group and affiliated collaborators, with limited but non-zero independent Western replication. Users should weigh this literature honestly — it represents a real, sustained research program conducted over three decades, but it does not carry the same evidentiary weight as an equivalent body of multi-center Western RCT data.

Russian preclinical literature (the majority of the evidence base):

• Cell culture and animal models — Multiple Russian publications report Pinealon effects on neuronal cell culture survival under oxidative and hypoxic stress, on aged rodent cognitive performance, and on molecular markers of neurodegeneration. Representative work includes [Arutjunyan et al. (2012)] on hypoxia protection, and studies from the Anisimov group on life-span effects in aged rats.
• Life-span studies — Khavinson's group has published work claiming that short peptide bioregulators including Pinealon extend mean and maximum life span in aged rats and mice. The magnitude of reported effects varies from modest (5–10% extension) to more striking (20%+ extension) depending on the peptide and study.
• Alzheimer's-model work — Published papers describe Pinealon effects in transgenic and sporadic Alzheimer's animal models, with claimed reductions in beta-amyloid accumulation and cognitive preservation.

Russian clinical gerontology literature:

• Khavinson et al. and collaborators have published clinical studies in aged populations using Pinealon and related peptides, with reported outcomes including improved cognitive scores on standard neuropsychological batteries, improvements in sleep quality, reduced incidence of age-related vascular and cognitive complications, and subjective quality-of-life improvements.
• Most of these studies are small (n = 30–200 per cohort), often without formal randomization or blinding by modern RCT standards, and were published in Russian-language journals with limited indexing in Western databases.
• A subset of studies have been translated and published in English-language journals (Neuroendocrinology Letters, Biogerontology, Advances in Gerontology), but these typically remain at the level of single-center experience rather than multi-center RCTs.

Western independent literature:

• A small number of Western labs have conducted independent studies on Khavinson peptides (primarily on Epitalon and Thymalin), with some positive findings on cellular effects.
• Pinealon specifically has received less independent Western attention than Epitalon.
• Most Western biomedical databases (PubMed, Web of Science) show Pinealon citations that trace back to Khavinson-group authors, sometimes in collaboration with Western authors.

Human commercial use in Russia:

• Pinealon is commercially available in Russia through various gerontology clinics, the Cytomed company's "Cytogen" peptide line, and compounding pharmacies serving the anti-aging clinical community.
• Russian clinical gerontology practice has integrated peptide bioregulators for several decades, primarily in residential clinics serving aging populations.
• Anecdotal user experience is substantial but uncontrolled; it is effectively a large, uncontrolled experiment in long-term Russian clinical practice.

What is missing from the evidence base:

• Multi-center, double-blind, placebo-controlled RCTs of Pinealon with cognitive outcomes as primary endpoints, conducted outside Russia with Western regulatory oversight
• Rigorous pharmacokinetic studies in humans after subcutaneous or intranasal administration
• Long-term safety surveillance from large populations outside Russian gerontology practice
• FDA or EMA regulatory evaluation
• Head-to-head comparisons with approved cognitive and neuroprotective interventions

How to weigh the evidence:

• If you give substantial weight to a sustained, multi-decade Russian clinical research program with consistent directional findings across many studies, Pinealon carries moderate evidence for neurocognitive support in aging populations.
• If you require Western-style RCT validation, Pinealon remains an unproven compound with interesting but preliminary evidence.
• Either interpretation is defensible given the state of the literature.

For readers seeking cognitive and neuroprotective support with stronger Western evidence bases, see lion's mane, omega-3 EPA/DHA, creatine, caffeine and L-theanine, and metformin. For readers already committed to the short-peptide bioregulator space and looking for adjacent compounds, see Epitalon, Selank, and Semax.

The side-effect profile of Pinealon, based on the available Russian clinical literature and user-reported experience, is described as mild and uncommon. Whether this reflects genuinely low toxicity or inadequate reporting in the available studies is a legitimate question, and users should treat "minimal side effects" claims with modest skepticism given the state of the evidence base.

Reported side effects in the Russian clinical literature:

• Injection site reactions — mild redness, tenderness, or swelling at subcutaneous injection sites; typically resolving within 24–48 hours
• Transient mild fatigue in the first days of administration
• Occasional mild headache
• Sleep changes — some users report improved sleep quality, while others report mild insomnia during adjustment, particularly if dosing is too close to bedtime
• Dry mouth or altered taste — rare
• Mild gastrointestinal discomfort with intranasal administration — rare

Theoretical concerns based on mechanism:

• Unknown long-term effects on neural tissue. The claim that Pinealon enters the brain and modulates gene expression in neurons, if true, implies long-term effects that have not been characterized with the rigor one would apply to a drug acting on the CNS. Multi-decade exposure data effectively does not exist outside Russian clinical practice.
• Interactions with natural melatonin and circadian signaling. A compound derived from pineal peptides could plausibly affect sleep-wake regulation, and dosing timing may matter.
• Immune or autoimmune effects. Unknown for Pinealon specifically, but short peptides as a class can occasionally trigger immune responses.
• Effects on neurodevelopmental processes. No pediatric data; not appropriate for children or adolescents.
• Interactions with neuroactive pharmaceuticals. Not characterized in humans. Users on antidepressants, anxiolytics, antipsychotics, anticonvulsants, or dementia medications should approach any Khavinson peptide cautiously.

Manufacturing and purity concerns:

• Pinealon sourced outside Russia is typically from research-chemical peptide suppliers. Purity varies; certificates of analysis are essential.
• Russian commercial sources (Cytomed and similar) are held to Russian pharmaceutical manufacturing standards but are not subject to FDA/EMA oversight.
• Contamination, sequence errors, and incorrect reconstitution can all contribute to side effects that are not intrinsic to the compound itself.

Who should not use Pinealon:

• Pregnancy and lactation — no data
• Pediatric use — no data
• Active seizure disorder or history of seizures — theoretical CNS effects
• Severe psychiatric illness without specialist oversight
• Active CNS infection or recent brain injury
• Active hormone-sensitive cancer (given pineal-melatonin pathway involvement)
• Known hypersensitivity to peptide products or vehicle components
• Users unable to obtain product from a reputable source with verified purity

Relative cautions:

• Concurrent use of melatonin or sleep pharmacotherapy (monitor for additive effects)
• Concurrent use of stimulants or cognitive enhancers (unclear interactions)
• Bleeding disorders or anticoagulation (minor risk at injection sites)
• Autoimmune disease (theoretical immune activation)

User-reported outcomes from body-hacking community sources:

• Most long-term users report good tolerability with minimal or no side effects across cycles
• A minority report subtle sleep changes, vivid dreams, or mild mood shifts
• No pattern of serious adverse events has emerged in the reported user community, though this does not rule out rare events in larger populations
• Occasional reports of product mislabeling or underdosing from less reputable suppliers

When to discontinue:

• Any new neurologic symptom (headache, vision change, seizure, confusion)
• Persistent sleep disruption despite dose timing adjustment
• Injection site reactions that worsen over time
• Any systemic symptom that appeared with peptide introduction and does not resolve on pause

The honest safety summary: Pinealon, at conservative research-community doses, appears to be reasonably well-tolerated based on available Russian clinical experience and user reports. The evidence is not robust enough to rule out rare or long-term adverse effects, and users should approach chronic use with appropriate humility. For readers seeking well-characterized cognitive and neuroprotective support with stronger safety datasets, approved and over-the-counter alternatives (detailed above) remain the lower-risk choice.